H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $192 from $198 and keeps a Buy rating on the shares. The firm says the company ended 2025 “with significant momentum.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences: Durable Ingrezza Growth and Emerging Crenessity Ramp Support Buy Rating Despite Near-Term Cost Pressures
- Buy Rating on Pullback: Solid Top-Line Growth, Ingrezza Strength, and Crenessity Blockbuster Potential Support Long-Term Upside
- Neurocrine Biosciences: Durable Franchise Momentum and Pipeline Investment Support Buy Rating
- Neurocrine reports Q4 adjusted EPS $1.88, consensus $2.30
- Neurocrine sees FY26 Ingrezza net product sales $2.7B-$2.8B